Karyopharm Therapeutics Inc.
KPTIDrugs in Pipeline
10
Phase 3 Programs
5
Upcoming Catalysts
9
Next Catalyst
Jun 30, 2026
4wMarket Overview
Stock performance and key metrics
9 upcoming, 0 past
Ruxolitinib
Myelofibrosis
Selinexor (combination therapy)
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Bortezomib
Multiple Myeloma
Dexamethasone
Multiple Myeloma
Selinexor
Multiple Myeloma, Refractory
KPT-8602
Relapsed/Refractory Multiple Myeloma (RRMM)
Selinexor 60 mg
Myelofibrosis
Hydroxyurea
Acute Myeloid Leukemia (AML)
Selinexor 100 mg
Non-Small Cell Lung Carcinoma (NSCLC)
Lenalidomide
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ruxolitinib | Phase 3 | Myelofibrosis | - | - |
Selinexor (combination therapy) | Phase 3 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Dexamethasone | Phase 3 | Multiple Myeloma | - | - |
Selinexor | Phase 3 | Multiple Myeloma, Refractory | - | - |
KPT-8602 | Phase 2 | Relapsed/Refractory Multiple Myeloma (RRMM) | - | - |
Selinexor 60 mg | Phase 2 | Myelofibrosis | - | - |
Hydroxyurea | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Selinexor 100 mg | Phase 2 | Non-Small Cell Lung Carcinoma (NSCLC) | - | - |
Lenalidomide | Phase 2 | Multiple Myeloma | - | - |